Alpine Immune Sciences Inc
ALPN
ALPN was delisted on the 17th of May, 2024.
70 hedge funds and large institutions have $255M invested in Alpine Immune Sciences Inc in 2022 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 4 closing their positions.
300% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 4
50% more capital invested
Capital invested by funds: $170M → $255M (+$85M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
33% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 18
21% more funds holding
Funds holding: 58 → 70 (+12)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$35.9M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$24M |
| 3 |
DCMIC
Decheng Capital Management III (Cayman)
Grand Cayman,
Cayman Islands
|
+$16.5M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$11.4M |
| 5 |
CC
Commodore Capital
New York
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$2.67M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$1.15M |
| 3 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$428K |
| 4 |
Renaissance Technologies
New York
|
-$319K |
| 5 |
Two Sigma Advisers
New York
|
-$273K |
ALPN Hedge Fund Activity: Q3 2022 in Review
70 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q3 2022, worth a combined $255M — up 50% from $170M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ALPN positions and 4 closed out — a net gain of 12 holders — while 24 added to existing stakes and 18 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $35.9M. The largest seller was TCG Crossover Management, cutting an estimated $2.67M.
- 70 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q3 2022, up from 58 in Q2 2022.
- Funds reported $255M of Alpine Immune Sciences Inc stock for Q3 2022, up 50% quarter-over-quarter.
- 16 funds opened new Alpine Immune Sciences Inc positions in Q3 2022 and 4 closed out, a net change of +12 holders.
- The largest Alpine Immune Sciences Inc buyer in Q3 2022 was RA Capital Management, an estimated $35.9M added.
- The largest Alpine Immune Sciences Inc seller in Q3 2022 was TCG Crossover Management, an estimated $2.67M sold.
Based on aggregated 13F filings for Q3 2022.